NeuroMab™ Anti-PADI2 BBB Shuttle Antibody, Clone #10
- Host Species:
- Mouse
- Species Reactivity:
- Rabbit
- Applications:
- ELISA; WB; Inhib; IHC; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1. The culture supernatant of mAb #1-35 was tested on human recombinant (hr) PAD2-coated plates.
hrPAD2 was diluted in 2-fold steps from 500 ng/mL. Shown is the absorbance at the coating concentration of 32 ng/mL. HRP-conjugated rabbit anti-mouse, diluted 1:1000, was added for 1 hour at RT, and the plates were developed with OPD substrate. The levels are given as OD490-650 nm-units.
Figure 2. mAbs reacted with hrPAD2 in western blotting.
Figure 3. Culture supernatant from mAb #1-35 tested on hrPAD2/hrPAD4 coated plates - 50 ng/mL.
HRP Rabbit anti-mouse (p0260) was added 1:1000 for 1 hour at RT and plates were developed with OPD substrate. The levels are given as OD490-650 nm-units.
Figure 4. Anti-PAD2 epitope mapping. Different splice variants of PAD2 were assessed by western blotting.
Shown is the reactivity of three selected mAbs (#2, #6 and #34) with WT (full length wild type human PAD2), C254 (amino acids 1-254 of human PAD2), 1385-463 (whole length human PAD2 without the catalytic site), N165 (from amino acid 165 to the C-terminus), N343 (from amino acid 343 to the C-terminus). The mAbs were found to bind in the N-terminal region among amino acids 1-165.
Figure 5. Inhibitory ability of anti-PAD2 monoclonal antibody. The ability of selected anti-PAD2 mAbs to inhibit fibrinogen citrullination was tested using human recombinant PAD2 (hrPAD2) as a catalyst.
Test of the inhibitory capacity of mAbs #2, #3 and #33. A mAb against human complement component 4 C4 (anti-C4) was used as negative control.
Figure 6. Inhibitory ability of anti-PAD2 mAb. The ability of selected anti-PAD2 mAbs to inhibit fibrinogen citrullination was tested using human recombinant PAD2 (hrPAD3) as a catalyst.
Test of the inhibitory capacity of mAbs #6, #8 and #10. Anti-C4 was used as control.
Figure 7. Inhibitory ability of anti-PAD2 mAb. The ability of selected anti-PAD2 mAbs to inhibit fibrinogen citrullination was tested using human recombinant PAD2 (hrPAD4) as a catalyst.
Test of the inhibitory capacity of culture supernatants (cs) from mAb #9, #12, #31 and #34 was tested. mAbs against chicken complement component 3 (chC3) and SCUBE1 (signal peptide, CUB domain, epidermal growth factor-like protein 1) was used as controls.
Publications (0)